Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
05 12월 2023 - 9:00PM
Business Wire
$2.3 million grant expected to drive research
to harness the host interferon response as a pathway to treating
and preventing pandemic influenza
Exscientia plc (Nasdaq: EXAI) announced today that the Company
received a $2.3 million grant from Open Philanthropy, a
philanthropic funder with several programs in global health and
wellbeing. Under this grant, Exscientia aims to harness the
activation of the host interferon response as a therapeutic
approach for pandemic influenza.
The grant comes in the context of the wider Pandemic Antiviral
Discovery (PAD) initiative. Out of the COVID-19 pandemic
experience, jointly with the Novo Nordisk Foundation and the Bill
& Melinda Gates Foundation, Open Philanthropy launched the PAD
initiative to help catalyse the discovery and early development of
novel antiviral medicines in preparation for future pandemics.
“We are thrilled that these expert institutions are supporting
Exscientia’s capabilities to develop innovative solutions to
address significant unsolved health issues, expressed through this
grant,” said Professor Ian Goodfellow, Vice President of Antivirals
at Exscientia. “If we manage to ‘turn on’ the interferon response,
in a highly controlled manner using small molecule therapeutics, we
may be able to transform the way influenza can be treated and
prevented in the future – an essential requirement of effective
pandemic preparedness.”
The research funded through this grant will allow Exscientia to
further explore the requirements for the activation of key aspects
of the interferon response of known antiviral effects against
influenza and COVID-19. The interferon response is a crucial
component of the body’s natural ability to control influenza virus
infection. Its activation results in the production of soluble
proteins that bind to the surface of epithelial cells that line the
respiratory tract and activate an antiviral state, suppressing
further viral replication.
This focus aligns with the company’s ongoing commitment to
pandemic preparedness, initiated with support from the Bill &
Melinda Gates Foundation in 2021. Over the long-term, by utilising
Exscientia’s AI-led drug discovery platform, the research funded
through this grant and any resulting chemical hits may bear
potential to be used in the design of potent and specific small
molecule drug candidates able to turn on the interferon response in
select tissues or cells relevant to influenza virus infection,
including future variants and other viruses.
“We are excited to help fund novel approaches to increasing
resilient response to infectious disease,” said Heather Youngs,
Senior Program Officer for Scientific Research at Open
Philanthropy. “The world needs diverse ready options to address
general global health needs and to prevent future pandemics and all
their dire consequences.”
About Exscientia
Exscientia is an AI-driven precision medicine company committed
to discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our internal
pipeline is focused on leveraging our precision medicine platform
in oncology, while our partnered pipeline broadens our approach to
other therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients.
Visit us at https://www.exscientia.ai or follow us on Twitter/X
@exscientiaAI.
Exscientia Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any statement describing Exscientia’s goals, plans,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to a number of risks,
uncertainties and assumptions. In light of these risks and
uncertainties, and other risks and uncertainties that are described
in the Risk Factors section and other sections of Exscientia’s
Annual Report on Form 20-F, filed with the Securities and Exchange
Commission (SEC) on March 23, 2022 (File No. 001-40850), and other
filings that Exscientia makes with the SEC from time to time (which
are available at https://www.sec.gov), the events and circumstances
discussed in such forward-looking statements may not occur, and
Exscientia’s actual results could differ materially and adversely
from those anticipated or implied thereby. Although Exscientia’s
forward-looking statements reflect the good faith judgement of its
management, these statements are based only on facts and factors
currently known by the Company at the time of this press release.
As a result, you are cautioned not to rely on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231205812217/en/
Investor Relations: Sara Sherman investors@exscientia.ai
Media: Oliver Stohlmann media@exscientia.ai
Exscientia (NASDAQ:EXAI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Exscientia (NASDAQ:EXAI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024